KR102835904B1 - N-치환된 테트라히드로티에노피리딘 유도체 및 이의 용도 - Google Patents

N-치환된 테트라히드로티에노피리딘 유도체 및 이의 용도

Info

Publication number
KR102835904B1
KR102835904B1 KR1020217001077A KR20217001077A KR102835904B1 KR 102835904 B1 KR102835904 B1 KR 102835904B1 KR 1020217001077 A KR1020217001077 A KR 1020217001077A KR 20217001077 A KR20217001077 A KR 20217001077A KR 102835904 B1 KR102835904 B1 KR 102835904B1
Authority
KR
South Korea
Prior art keywords
compound
cyano
alkyl
mmol
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217001077A
Other languages
English (en)
Korean (ko)
Other versions
KR20210022645A (ko
Inventor
시릴 쿤드
웨이 린 산드라 심
올리버 사이먼
강 왕
후이 취안 예오
브라이언 케이에스 영
후미아키 요코카와
빈 저우
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67841114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102835904(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20210022645A publication Critical patent/KR20210022645A/ko
Application granted granted Critical
Publication of KR102835904B1 publication Critical patent/KR102835904B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217001077A 2018-06-19 2019-06-18 N-치환된 테트라히드로티에노피리딘 유도체 및 이의 용도 Active KR102835904B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687068P 2018-06-19 2018-06-19
US62/687,068 2018-06-19
PCT/IB2019/055121 WO2019244047A1 (en) 2018-06-19 2019-06-18 N-substituted tetrahydrothienopyridine derivatives and uses thereof

Publications (2)

Publication Number Publication Date
KR20210022645A KR20210022645A (ko) 2021-03-03
KR102835904B1 true KR102835904B1 (ko) 2025-07-22

Family

ID=67841114

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217001077A Active KR102835904B1 (ko) 2018-06-19 2019-06-18 N-치환된 테트라히드로티에노피리딘 유도체 및 이의 용도

Country Status (24)

Country Link
US (3) US12012417B2 (https=)
EP (2) EP4169925B1 (https=)
JP (1) JP7328260B2 (https=)
KR (1) KR102835904B1 (https=)
CN (1) CN112313237A (https=)
AU (1) AU2019291488B2 (https=)
BR (1) BR112020025696A2 (https=)
CA (1) CA3100957A1 (https=)
CL (1) CL2020003248A1 (https=)
CR (1) CR20200618A (https=)
CU (1) CU20200100A7 (https=)
EA (1) EA202190046A1 (https=)
EC (1) ECSP20080995A (https=)
ES (2) ES3062606T3 (https=)
IL (1) IL279441B2 (https=)
JO (1) JOP20200326A1 (https=)
MA (1) MA52976A (https=)
MX (1) MX2020013852A (https=)
MY (1) MY201990A (https=)
PE (1) PE20210097A1 (https=)
PH (1) PH12020552185A1 (https=)
SA (1) SA520420809B1 (https=)
SG (1) SG11202012625PA (https=)
WO (1) WO2019244047A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3663299B1 (en) * 2017-08-01 2023-03-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound acting as ror gamma inhibitor
BR112020025696A2 (pt) 2018-06-19 2021-03-16 Novartis Ag Derivados de tetra-hidrotienopiridina n-substituída e usos dos mesmos
USD1006154S1 (en) * 2023-06-27 2023-11-28 Qiongfang Mao Cable crossover attachment
WO2025238553A1 (en) 2024-05-14 2025-11-20 Novartis Ag Dosing regimens for n-(3-cyano-5-(cyclohexylmethyl)-6,6-dimethyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-2-(4-sulfamoylphenyl)acetamide for use in treating or preventing a dengue virus disease or disorder
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092156A1 (en) 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
WO2010099166A1 (en) 2009-02-27 2010-09-02 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections
US20130129677A1 (en) 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
WO2018215316A1 (en) 2017-05-22 2018-11-29 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807A (en) 1848-09-26 Brake fob cabs
US6344A (en) 1849-04-17 Driving-bobbin
US498178A (en) 1893-05-23 William valentine leonard
US4656A (en) 1846-07-24 Improvement in potato-plows
US8766A (en) 1852-02-24 Appabatus for lightening vessels
US54472A (en) 1866-05-01 Improved blacking-brush
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CA2252465C (en) 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
CA2367017C (en) 1999-03-19 2009-05-26 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
DE60236428D1 (de) 2001-05-21 2010-07-01 Monsanto Technology Llc Etheramin-tenside enthaltende pestizidkonzentrate
US20030232994A1 (en) 2001-10-04 2003-12-18 Shao-Po Lu Bicyclic thiophene derivatives and combinatorial libraries thereof
CA2498399A1 (en) 2002-09-12 2004-03-25 Merck & Co., Inc. Method of treating diabetes and related conditions
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
ES2309765T3 (es) 2004-05-28 2008-12-16 4Sc Ag Tetrahidropiridotiofenos.
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
EP1851229A1 (en) 2005-02-09 2007-11-07 Nycomed GmbH Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
AU2006212179A1 (en) 2005-02-11 2006-08-17 4Sc Ag Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
US7714136B2 (en) 2005-05-25 2010-05-11 4Sc Ag Tetrahydropyridothiophenes
US7763728B2 (en) 2005-05-25 2010-07-27 4Sc Ag Tetrahydropyridothiophenes
US7932391B2 (en) 2005-09-08 2011-04-26 Zhejiang Hauhai Pharmaceutical Co., Ltd. Method for the preparation of clopidogrel and its analogues of methyl-tetrahydrothieno[3,2-C]pyridine acetate
WO2008020024A1 (en) 2006-08-16 2008-02-21 4Sc Ag Ntetrahydropyridothiophene derivatives for the treatment of cancer
WO2008020045A1 (en) 2006-08-16 2008-02-21 4Sc Ag Tetrahydrobenzothiophene derivatives
WO2008067222A1 (en) 2006-11-28 2008-06-05 Kalypsys, Inc. Heterocyclic modulators of tgr5
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5701655B2 (ja) 2011-03-29 2015-04-15 奈良県 植物精油中のトロポロン類及び／又はフェノール類の金属錯体化方法
AP2014007595A0 (en) 2011-09-30 2014-04-30 Kineta Inc Anti-viral compounds
US10844051B2 (en) 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
CN108689987A (zh) * 2017-04-05 2018-10-23 浙江海正药业股份有限公司 一种磺胺类衍生物及其制备方法和用途
EP3663299B1 (en) 2017-08-01 2023-03-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound acting as ror gamma inhibitor
CN108191885B (zh) * 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
BR112020025696A2 (pt) 2018-06-19 2021-03-16 Novartis Ag Derivados de tetra-hidrotienopiridina n-substituída e usos dos mesmos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092156A1 (en) 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
WO2010099166A1 (en) 2009-02-27 2010-09-02 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections
US20130129677A1 (en) 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
WO2018215316A1 (en) 2017-05-22 2018-11-29 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Michael Podvinec et al. Journal of Medicinal Chemistry, 2010, Vol. 53, No. 4, pp. 1483-1495

Also Published As

Publication number Publication date
CL2020003248A1 (es) 2021-07-09
MA52976A (fr) 2021-04-28
US20220073535A1 (en) 2022-03-10
EP4169925A3 (en) 2023-06-14
US20260070920A1 (en) 2026-03-12
CN112313237A (zh) 2021-02-02
CR20200618A (es) 2021-01-21
ES3062606T3 (en) 2026-04-13
JP7328260B2 (ja) 2023-08-16
SG11202012625PA (en) 2021-01-28
US12331060B2 (en) 2025-06-17
AU2019291488B2 (en) 2022-02-24
EP3810613A1 (en) 2021-04-28
JOP20200326A1 (ar) 2020-12-14
IL279441A (en) 2021-01-31
SA520420809B1 (ar) 2022-08-17
ES2941946T3 (es) 2023-05-26
JP2021529159A (ja) 2021-10-28
PE20210097A1 (es) 2021-01-12
MX2020013852A (es) 2021-05-27
AU2019291488A1 (en) 2021-02-04
EA202190046A1 (ru) 2021-03-24
KR20210022645A (ko) 2021-03-03
CU20200100A7 (es) 2021-08-06
MY201990A (en) 2024-03-27
BR112020025696A2 (pt) 2021-03-16
EP4169925B1 (en) 2025-11-19
EP3810613B1 (en) 2023-01-11
ECSP20080995A (es) 2021-02-26
WO2019244047A1 (en) 2019-12-26
IL279441B2 (en) 2023-06-01
PH12020552185A1 (en) 2021-06-07
CA3100957A1 (en) 2019-12-26
US20240352030A1 (en) 2024-10-24
EP4169925A2 (en) 2023-04-26
US12012417B2 (en) 2024-06-18

Similar Documents

Publication Publication Date Title
KR102835904B1 (ko) N-치환된 테트라히드로티에노피리딘 유도체 및 이의 용도
CN113286794B (zh) Kras突变蛋白抑制剂
TWI855062B (zh) Bcl-2抑制劑
EP3692028B1 (en) Inhibiting ubiquitin specific peptidase 30
CA3078312A1 (en) Substituted fused tetra-cyclic 4-oxo-1,4-dihydropyridine derivatives and pharmaceutical compositions thereof useful for treatment of hbv
CN112585118A (zh) 乙型肝炎衣壳装配调节剂
KR20180002811A (ko) RORγ 조정제로서의 트리시클릭 술폰
JP2025528804A (ja) イソインドリン置換グルタルイミド骨格に基づく化合物、及びその応用
WO2024140637A1 (zh) 氧代异吲哚啉基取代哌啶二酮衍生物及其应用
KR20230035049A (ko) 화합물, 조성물 및 방법
CN115043836A (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
US20180334436A1 (en) Tetrahydroisoquinoline derivatives
JP2022553284A (ja) Ｔｒｅｋ（ｔｗｉｋ関連ｋ＋チャネル）チャネル機能の阻害剤
RU2776476C2 (ru) N-замещенные производные тетрагидротиенопиридина и их применение
JP2025533996A (ja) シアノ置換含有ポリペプチド系化合物の結晶及びその製造方法
HK40041690B (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
HK40041690A (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
EA041825B1 (ru) N-замещенные производные тетрагидротиенопиридина и их применение
WO2026002044A1 (zh) 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用
WO2025162225A1 (zh) 具有取代的戊二酰亚胺基异吲哚啉酮新颖骨架的化合物及其应用
WO2025162221A1 (zh) 基于取代的异吲哚啉酮新颖骨架化合物、含有其的双功能蛋白降解剂及它们的应用
CN121318828A (zh) 一种炎症小体抑制剂及其应用
BR122025008865A2 (pt) Compostos antimaláricos, composições farmacêuticas compreendendo os mesmos e usos
HK40042077A (en) Hepatitis b capsid assembly modulators
HK40036033A (en) Inhibiting ubiquitin specific peptidase 30

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)